Sign In
Buy KYTX
$7.82
-0.0800 (-1.01%)
At Close: Jun 03, 2026
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Kyverna Therapeutics, Inc. (KYTX) on Behalf of Investors
03:00pm, Thursday, 12'th Dec 2024
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Kyverna Therapeutics, Inc. (“Kyverna” or the “Company”) (NASDAQ: KYTX) investors concerni
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Kyverna Thera
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 7, 2025 in Kyverna Therapeutics, Inc. Lawsuit - KYTX
12:15pm, Thursday, 12'th Dec 2024
NEW YORK, NY / ACCESSWIRE / December 12, 2024 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securi
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Kyverna To Contact Him Directly To Discuss Their Options If you suf
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 7, 2025 in Kyverna Therapeutics, Inc. Lawsuit - KYTX
07:25am, Thursday, 12'th Dec 2024
NEW YORK, NY / ACCESSWIRE / December 12, 2024 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securi
NEW YORK, NY / ACCESSWIRE / December 12, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Kyverna Ther
SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements re: Kyverna business and prospects, resulting in its stock trading at inflated prices.
Lost Money on Kyverna Therapeutics, Inc.(KYTX)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky
09:35pm, Wednesday, 11'th Dec 2024
NEW YORK, NY / ACCESSWIRE / December 11, 2024 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securi
NEW ORLEANS, LA / ACCESSWIRE / December 11, 2024 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until Feb
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Kyverna Therapeutics, Inc.(KYTX) Shareholders
09:00pm, Wednesday, 11'th Dec 2024
NEW YORK, NY / ACCESSWIRE / December 11, 2024 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securi
NEW YORK, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Kyverna Thera
LOS ANGELES, CA / ACCESSWIRE / December 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces the firm has filed a class action lawsuit against Kyverna Therapeutics,
The Law Offices of Frank R. Cruz Announces Investigation of Kyverna Therapeutics, Inc. (KYTX) on Behalf of Investors
07:04pm, Wednesday, 11'th Dec 2024
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Kyverna Therapeutics, Inc. (“Kyverna” or the “Company”) (NASDAQ: KYTX) on behalf of investors conce
Investors in Kyverna Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX
06:15pm, Wednesday, 11'th Dec 2024
NEW YORK, NY / ACCESSWIRE / December 11, 2024 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securi
NEW YORK, Dec. 11, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Kyverna Therapeutics, Inc.
